What If There Was a Way to treat Heart Failure (HF) Patients without Opening Their Chest? There Is, and BioVentrix Is Making It Possible
In the US and EU, HF is one of the most frequent diagnoses, and accounts for 7.5 million hospital days per year. Three to five percent of patients die despite hospitalization, half go home unimproved, 25% are readmitted within 30 days, and 30% die in six months.